Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Trevor S. Johnston et al.|medRxiv|2022Cited by 21
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccinationTeresa Po‐Yu Chiang, William A. Werbel, Jennifer L. Alejo et al.|American Journal of Transplantation|2022Cited by 19
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipientsAndrew H. Karaba, William A. Werbel, Jake D. Kim et al.|American Journal of Transplantation|2023Cited by 12
230.6: Ad.26.COV2.S Versus BNT162b2 or mRNA-1273 as a Third Dose in Solid Organ Transplant Recipients Seronegative After 2-dose mRNA VaccinationTeresa Po‐Yu Chiang, William A. Werbel, Jennifer L. Alejo et al.|Transplantation|2022Cited by 0